Glaukos Corporation announced preliminary, unaudited net sales of approximately $143 million for the fourth quarter of 2025, representing a 36% increase over Q4 2024. U.S. Glaucoma net sales were approximately $86 million, including iDose® TR net sales of $45 million. International Glaucoma net sales reached $33 million, while Corneal Health products contributed $24 million. For the full year ended December 31, 2025, total net sales are expected to be $507 million, up 32% year-over-year. That annual performance comprised $299 million in U.S. Glaucoma net sales (including $136 million from iDose TR), $122 million in International Glaucoma net sales, and $86 million from Corneal Health. The company closed the quarter with $283 million in cash, short-term investments and restricted cash, carried no debt, and reaffirmed 2026 revenue guidance of $600 million to $620 million.

At the 44th Annual J.P. Morgan Healthcare Conference, Chairman and CEO Thomas Burns, together with President Joe Gilliam and CFO Alex Thurman, emphasized Glaukos’s role as a pioneer in ophthalmology. The company underscored its leadership in the global micro-invasive glaucoma surgery (MIGS) market and detailed ongoing launches in procedural pharmaceuticals, led by iDose, which delivers sustained intracameral therapy. Executives highlighted expansion into corneal cross-linking for keratoconus, a rare disease indication, and previewed a transdermal topical platform designed to deliver active pharmaceutical ingredients to the anterior segment—an innovation never before attempted. Burns reiterated confidence in advancing a robust dropless-drug pipeline aimed at improving chronic eye disease outcomes and sustaining double-digit growth over the next several years.